- Home
- NWN vs JANX Comparison
NWN vs JANX Comparison
Compare NWN & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWN
- JANX
- Stock Information
- Founded
- NWN 1859
- JANX 2017
- Country
- NWN United States
- JANX United States
- Employees
- NWN N/A
- JANX N/A
- Industry
- NWN Oil/Gas Transmission
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- NWN Utilities
- JANX Health Care
- Exchange
- NWN Nasdaq
- JANX Nasdaq
- Market Cap
- NWN 1.7B
- JANX 1.4B
- IPO Year
- NWN N/A
- JANX 2021
- Fundamental
- Price
- NWN $46.00
- JANX $27.81
- Analyst Decision
- NWN Buy
- JANX Strong Buy
- Analyst Count
- NWN 2
- JANX 11
- Target Price
- NWN $48.00
- JANX $76.55
- AVG Volume (30 Days)
- NWN 229.7K
- JANX 1.2M
- Earning Date
- NWN 11-05-2025
- JANX 11-06-2025
- Dividend Yield
- NWN 4.26%
- JANX N/A
- EPS Growth
- NWN 17.48
- JANX N/A
- EPS
- NWN 2.58
- JANX N/A
- Revenue
- NWN $1,238,288,000.00
- JANX $439,000.00
- Revenue This Year
- NWN $17.95
- JANX N/A
- Revenue Next Year
- NWN $5.66
- JANX $89.91
- P/E Ratio
- NWN $17.83
- JANX N/A
- Revenue Growth
- NWN 8.40
- JANX N/A
- 52 Week Low
- NWN $38.03
- JANX $21.73
- 52 Week High
- NWN $47.79
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- NWN 56.41
- JANX 57.14
- Support Level
- NWN $46.76
- JANX $24.30
- Resistance Level
- NWN $47.77
- JANX $31.59
- Average True Range (ATR)
- NWN 0.81
- JANX 1.86
- MACD
- NWN 0.01
- JANX 0.18
- Stochastic Oscillator
- NWN 56.72
- JANX 48.18
About NWN Northwest Natural Holding Company
Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company operates in one reportable business segment, which is NW Natural's local gas distribution business and is referred to as the NGD segment. The company generates its revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.